Walgreens Boots Alliance Posts Lower Q2 Profits On Falling COVID-19 Vaccination, Reaffirms Annual Guidance

  • Walgreens Boots Alliance Inc's WBA Q2 FY23 sales increased 3.3% Y/Y to $34.9 billion, up 4.5% on a constant currency basis, beating the consensus of $33.53 billion.
  • Adjusted EPS reached $1.16, unchanged from Q1 FY23 and down 25.8% on a constant currency basis, reflecting a 26% headwind from lower COVID-19 vaccine and testing volumes, beating the consensus of $1.10.
  • Adjusted operating income was $1.2 billion, down 25.4% on a constant currency basis, reflecting lower volumes of COVID-19 vaccinations and testing lapping the year-ago period's Omicron surge.
  • Related: New York Governor, Attorney General Ask Three Pharmacy Operators' Commitment Over Abortion Drug Access.
  • The company said it administered 2.4 million COVID-19 vaccinations in the quarter, down from around 11.8 million a year earlier.
  • U.S. pharmacy comparable script volume growth of 3.5 percent, excluding immunizations, ahead of expectations and sequentially improving vs. Q1 FY23.
  • Guidance: Walgreens maintains FY23 adjusted EPS of $4.45-$4.65 (consensus of $4.48) as strong core business growth is more than offset by lapping peak COVID-19 demand; pivoting to mid-twenties percent adjusted EPS growth in the second half of fiscal 2023 at the midpoint
  • Price Action: WBA shares are up 1.18% at $33.33 during the premarket session on the last check Tuesday.
  • Photo via Wikimedia Commons
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsLarge CapNewsGuidanceHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!